Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: A study of 63 cases from four different institutions

Modern Pathology

Volumn 29, Issue 1, 2016, Pages 25-33

  Khoury, Thaer ^a   Kumar, Prasanna R ^a   Li, Zaibo ^b   Karabakhtsian, Rouzan G ^c   Sanati, Souzan ^d   Chen, Xiwei ^a   Wang, Dan ^a   Liu, Song ^a   Reig, Beatriu ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST PAPILLOMA; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LOBULAR NEOPLASIA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; LARGE CORE NEEDLE BIOPSY; LUNG CARCINOMA; MAMMOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; PROGNOSIS;

EID: 84952717464     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.128     Document Type: Article

References (35)

1. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;78:1024-1034.
2. Chuba PJ, Hamre MR, Yap J et al. Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23:5534-5541.
3. Collins LC, Baer HJ, Tamimi RM et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2007;109:180-187.
4. O'Malley FP. Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol 2010;23(Suppl 2):S14-S25.
5. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143:446-457.
6. Simpson PT, Gale T, Fulford LG et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003;5:258-262.
7. Lakhani SR. In-situ lobular neoplasia: time for an awakening. Lancet 2003;361:96.
8. Mastracci TL, Shadeo A, Colby SM et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. Genes Chromosomes Cancer 2006;45:1007-1017.
9. Page DL, Schuyler PA, Dupont WD et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361:125-129.
10. Foote F, Stewart F. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941;17: 491-496.
11. Rosen PP, Senie R, Schottenfeld D et al. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 1979;189: 377-382.
12. Lechner MD, Park SL, Jackman RJ et al. Lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous biopsy with surgical correlation: a multiinstitutional study. Radiology 1999;213:106.
13. Chaudhary S, Lawrence L, McGinty G et al. Classic lobular neoplasia on core biopsy: a clinical and radiopathologic correlation study with follow-up excision biopsy. Mod Pathol 2013;26:762-771.
14. Lakhani SR, Schnitt SJ, O'Malley F et al. Lobular neoplasia. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds). World Health Organization classification of tumors of the breast 4th (edn). International Agency of Research and Cancer (IARC): Lyon, France, 2012;78-80.
15. National Comprehensive Cancer Network (US). Clinical practice guidelines in oncology, breast cancer v 2. 2015. National Comprehensive Cancer Network (US): Fort Washington (PA), 2015, Available from http:// www. nccn. org/professionals/physician-gls/pdf/breast. pdf (accessed on 25 June 2015).
16. Kuhl C. Current status of breast MR imaging Part 2. Radiology 2007;244:672-691.
17. Bevers TB, Anderson BO, Bonaccio E et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009;7:1060-1096.
18. Scoggins M, Krishnamurthy S, Santiago L et al. Lobular carcinoma in situ of the breast: clinical, radiological, and pathological correlation. Acad Radiol 2013;20: 463-470.
19. Khoury T, Karabakhtsian RG, Mattson D et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathol 2014;64:981-993.
20. Heller SL, Hernandez O, Moy L. Radiologic-pathologic correlation at breast MR imaging what is the appropriate management for high-risk lesions? Magn Reson Imaging Clin N Am 2013;21:583-599.
21. Liberman L, Bracero N, Morris E et al. MRI-guided 9-gauge vacuum-assisted breast biopsy: initial clinical experience. AJR Am J Roentgenol 2005;185: 183-193.
22. Orel SG, Rosen M, Mies C et al. MR imaging guided 9-gauge vacuum-assisted core-needle breast biopsy: initial experience. Radiology 2006;238:54-61.
23. Mahoney MC. Initial clinical experience with a new MRI vacuum-assisted breast biopsy device. J Magn Reson Imaging 2008;28:900-905.
24. Noroozian M, Gombos EC, Chikarmane S et al. Factors that impact the duration of MRI-guided core needle biopsy. AJR Am J Roentgenol 2010;194: W150-W157.
25. Strigel RM, Eby PR, Demartini WB et al. Frequency, upgrade rates, and characteristics of high-risk lesions initially identified with breast MRI. AJR Am J Roentgenol 2010;195:792-798.
26. Malhaire C, El Khoury C, Thibault F et al. Vacuum assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol 2010;20:1554-1562.
27. Heller SL, Elias K, Gupta A et al. Outcome of high-risk lesions at MRI-guided 9-gauge vacuumassisted breast biopsy. Am J Roentgenol 2014;202: 237-245.
28. Wheeler JE, Enterline HT, Roseman JM et al. Lobular carcinoma in situ of the breast. Long-term follow-up. Cancer 1974;34:554-563.
29. Andersen JA. Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 1977;39: 2597-2602.
30. Rosen PP, Kosloff C, Lieberman PH et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-251.
31. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006;4:511-522.
32. Ely KA, Carter BA, Jensen RA et al. Core biopsy of the breast with atypical ductal hyperplasia. A probabilistic approach to reporting. Am J Surg Pathol 2001;25: 1017-1021.
33. Wagoner MJ, Laronga C, Acs G. Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ. Am J Clin Pathol 2009;131:112-121.
34. Houssami N, Ciatto S, Ellis I et al. Underestimation of malignancy of breast core-needle biopsy. Cancer 2007;109:487-495.
35. Khoury T, Li Z, Sanati S et al. The risk of upgrade for atypical ductal hyperplasia detected on MRI-guided biopsy: a study of 100 cases from four academic institutions. Histopathol 2015;PMID:26291517 (epub ahead of print).